63 results on '"Pecciarini, L"'
Search Results
2. 55P EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
- Author
-
Riva, S.T., Ogliari, F.R., Cangi, M.G., Bucci, G., Foggetti, G., Ferrara, R., Pecciarini, L., Oresti, S., Viganò, M.G., Damiano, G., Gandolfi, G., Guzzeloni, V., Valci, S., Ferrara, M., Nuccio, A., Venanzi, F.M., Pilotto, S., Bulotta, A., Milella, M., and Reni, M.
- Published
- 2023
- Full Text
- View/download PDF
3. Stress und Frühgeburt: Neuroendokriner Hintergrund von akutem und chronischem Stress als Auslöser für eine Frühgeburt
- Author
-
Petraglia, F., Florio, P., Torricelli, M., Guidoni, C., Ignacchiti, E., Picciolini, E., Ciarmela, P., Fiore, G., Rossi, M., Severi, F. M., and Pecciarini, L.
- Published
- 2003
- Full Text
- View/download PDF
4. Chlamydia psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma
- Author
-
Ferreri, A. J. M., Dognini, G. P., Ponzoni, M., Pecciarini, L., Cangi, M. G., Santambrogio, G., Resti, A. G., De Conciliis, C., Magnino, S., Pasini, E., Vicari, N., Dolcetti, R., and Doglioni, C.
- Published
- 2008
5. Relationship between mode of delivery and neonatal calcium homeostasis
- Author
-
Bagnoli, F., Bruchi, S., Garosi, G., Pecciarini, L., and Bracci, R.
- Published
- 1990
- Full Text
- View/download PDF
6. SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE‐DENSE SHORT‐TERM THERAPY IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA AND MYC REARRANGEMENT.
- Author
-
Ferreri, A. J. M, Angelillo, P, Erbella, F, Liberatore, C, Cattaneo, C, Verga, L, Lleshi, A, Allione, B, Facchetti, F, Ponzoni, M, Pagani, C, Foppoli, M, Pecciarini, L, Sassone, M. C, Flospergher, E, Rossi, G, Spina, M, and A. Re
- Published
- 2021
- Full Text
- View/download PDF
7. Syndecan-1 (CD138) expression in human breast carcinoma is associated with an aggressive phenotype and appears related to a poor prognosis and low response to adjuvant chemotherapy
- Author
-
Galligioni, E., Barbareschi, M., Aldovini, D., Maisonneuuve, P., Cangi, M.G., Pecciarini, L., Caffo, O., Arcuri, C., Dalla Palma, P., and Doglioni, C.
- Published
- 2001
- Full Text
- View/download PDF
8. A woman and her canry: a tale of chlamydiae and lymphomas.
- Author
-
Ferreri AJM, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, and Ponzoni M
- Published
- 2007
- Full Text
- View/download PDF
9. Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.
- Author
-
Rimini M, Presi S, Pipitone GB, Russo Raucci A, Ratti F, Della Corte A, Pedica F, Vanella G, Tonon G, Burgio V, Vitiello F, Rossari F, Amadeo E, Maria Giulia C, Pecciarini L, Arcidiacono PG, Falcinelli F, Cascinu S, De Cobelli F, Aldrighetti L, Patricelli MG, Carrera P, and Casadei-Gardini A
- Subjects
- Humans, Biomarkers, Tumor genetics, Phenotype, Predictive Value of Tests, Risk Factors, Biliary Tract Neoplasms genetics, Biliary Tract Neoplasms therapy, Genetic Counseling, Genetic Predisposition to Disease, Genetic Testing, Germ-Line Mutation
- Abstract
Introduction: A genetic predisposition seems to be involved in biliary tract cancer, but the prevalence of germline mutations in BTC remains unclear, and the therapeutic role of the germline pathologic variants is still unknown., Area Covered: The aim of the present work is to systematically review the data available on the hereditary predisposition of biliary tract cancer by a specific research on PubMed, in order to highlight the most important critical points and to define the current possible role of germinal testing and genetic counseling in this setting of patients., Expert Opinion: Basing on data already available, we decided to start in our institution a specific genetic protocol focused on biliary tract cancer patients, which includes genetic counseling and, if indicated, germline test. The inclusion criteria are: 1) Patient with personal history of oncologic disease other than BTC, 2) Patient with familiar history of oncologic disease (considering relatives of first and second grade), 3) Patient with ≤ 50 years old, 4) Patient presenting a somatic mutation in genes involved in DNA damage repair pathways and mismatch repair. The aim of the presented protocol is to identify germline pathogenic variants with prophylactic and therapeutic impact, and to collect and integrate a significant amount of clinical, familial, somatic, and genetic data.
- Published
- 2024
- Full Text
- View/download PDF
10. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples.
- Author
-
Redegalli M, Grassini G, Magliacane G, Pecciarini L, Schiavo Lena M, Smart CE, Johnston RL, Waddell N, Maestro R, Macchini M, Orsi G, Petrone MC, Rossi G, Balzano G, Falconi M, Arcidiacono PG, Reni M, Doglioni C, and Cangi MG
- Subjects
- Humans, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Pancreatic Neoplasms, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms genetics, Pancreatic Neoplasms surgery, Adenocarcinoma diagnosis, Adenocarcinoma genetics, Adenocarcinoma surgery, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal surgery
- Abstract
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease, for which it is crucial to promptly detect actionable and prognostic alterations to drive specific therapeutic decisions, regardless of tumor resectability status. Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) is of key importance for PDAC diagnosis and can contribute significantly to tumor molecular profiling., Methods: Comprehensive genomic profile by targeted next-generation sequencing (NGS) was performed on 2 independent PDAC patient cohorts. Cohort 1 consisted of 77 patients with resectable PDAC for whom the histologic sample at the time of resection was available; for 56 patients cytologic specimens at the time of diagnosis also were obtained by EUS-FNA. Cohort 2 consisted of 20 patients with unresectable PDAC, for whom only the EUS-FNA cytologic sample was available., Results: In cohort 1, a complete concordant mutational profile between the cytologic sample at diagnosis and the corresponding histologic specimen after surgery was observed in 88% of the cases, proving the ability to detect potential clinically relevant alterations in cytologic samples by NGS analysis. Notably, clinically actionable mutations were identified in 20% of patients. In cohort 2, comprehensive mutational profiling was obtained successfully for all samples. Consistent with the findings of cohort 1, KRAS, TP53, CDKN2A, and SMAD4 were the most altered genes. Most importantly, 15% of the patients harbored actionable mutations., Conclusions: Our findings show the feasibility of an NGS approach using both surgical specimens and cytologic samples. The model proposed in this study can be included successfully in the clinical setting for comprehensive molecular profiling of all PDAC patients irrespective of their surgical eligibility., (Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
- Author
-
Pecciarini L, Brunetto E, Grassini G, De Pascali V, Ogliari FR, Talarico A, Marra G, Magliacane G, Redegalli M, Arrigoni G, Lazzari C, Gregorc V, Bulotta A, Doglioni C, and Cangi MG
- Subjects
- Humans, Anaplastic Lymphoma Kinase genetics, In Situ Hybridization, Fluorescence methods, Receptor Protein-Tyrosine Kinases genetics, RNA therapeutic use, Gene Fusion genetics, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung pathology, Adenocarcinoma of Lung
- Abstract
The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.
- Published
- 2023
- Full Text
- View/download PDF
12. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
- Author
-
Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegalli M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, and Cangi MG
- Abstract
Assessment of HRD status is now essential for ovarian cancer patient management. A relevant percentage of high-grade serous carcinoma (HGSC) is characterized by HRD, which is caused by genetic alterations in the homologous recombination repair (HRR) pathway. Recent trials have shown that not only patients with pathogenic/likely pathogenic BRCA variants, but also BRCAwt /HRD patients, are sensitive to PARPis and platinum therapy. The most common HRD test is Myriad MyChoice CDx, but there is a pressing need to offer an alternative to outsourcing analysis, which typically requires high costs and lengthy turnaround times. In order to set up a complete in-house workflow for HRD testing, we analyzed a small cohort of HGSC patients using the CE-IVD AmoyDx HRD Focus Panel and compared our results with Myriad's. In addition, to further deepen the mechanisms behind HRD, we analyzed the study cohort by using both a custom NGS panel that analyzed 21 HRR-related genes and FISH analysis to determine the copy numbers of PTEN and EMSY . We found complete concordance in HRD status detected by the Amoy and the Myriad assays, supporting the feasibility of internal HRD testing.
- Published
- 2022
- Full Text
- View/download PDF
13. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
- Author
-
Ferreri AJM, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, Allione B, Ponzoni M, Facchetti F, Pagani C, Foppoli M, Pecciarini L, Sassone M, Steffanoni S, Flospergher E, Rossi G, Spina M, and Re A
- Subjects
- Humans, Rituximab therapeutic use, Vincristine adverse effects, Etoposide adverse effects, Retrospective Studies, In Situ Hybridization, Fluorescence, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols adverse effects, Transplantation, Autologous, Cyclophosphamide adverse effects, Prednisone therapeutic use, Cytarabine adverse effects, Doxorubicin adverse effects, Hematopoietic Stem Cell Transplantation, COVID-19, Burkitt Lymphoma drug therapy, Burkitt Lymphoma genetics, Lymphoma, B-Cell drug therapy, Lymphoma drug therapy, HIV Infections drug therapy
- Abstract
Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n = 46) or high-grade B-cell lymphoma ([HGBCL] single, double, or triple hit; n = 22) were treated with a dose-dense, short-term therapy termed "CARMEN regimen" at 5 Italian centers. Forty-six (68%) patients were HIV+. CARMEN included a 36-day induction with sequential, single weekly doses of cyclophosphamide, vincristine, rituximab, methotrexate, etoposide, and doxorubicin plus intrathecal chemotherapy, followed by high-dose-cytarabine-based consolidation. Patients who did not achieve complete remission (CR) after induction received BEAM (carmustina, etoposide, cytarabine, melfalan)-conditioned autologous stem cell transplantation (ASCT) after consolidation. Sixty-one (90%) patients completed induction, and 59 (87%) completed consolidation. Seventeen patients received ASCT. Grade 4 hematological toxicity was common but did not cause treatment discontinuation; grade 4 nonhematological toxicity was recorded in 11 (16%) patients, with grade 4 infections in 6 (9%). Six (9%) patients died of toxicity (sepsis in 4, COVID-19, acute respiratory distress syndrome). CR rate after the whole treatment was 73% (95% confidence interval [CI], 55% to 91%) for patients with HGBCL and 78% (95% CI, 66% to 90%) for patients with BL. At a median follow-up of 65 (interquartile range, 40-109) months, 48 patients remain event free, with a 5-year progression-free survival of 63% (95% CI, 58% to 68%) for HGBCL and 72% (95% CI, 71% to 73%) for BL, with a 5-year overall survival (OS) of 63% (95% CI, 58% to 68%) and 76% (95% CI, 75% to 77%), respectively. HIV seropositivity did not have a detrimental effect on outcome. This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas. Encouraging survival figures, attained with a single dose of doxorubicin and cyclophosphamide, deserve further investigation in HGBCL and other aggressive lymphomas., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.
- Author
-
Lazzari C, Pecciarini L, Doglioni C, Pedica F, Gajate AMS, Bulotta A, Gregorc V, and Cangi MG
- Abstract
Rearrangements involving the neurotrophin kinase ( NTRK ) genes NTRK1 , NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Lazzari, Pecciarini, Doglioni, Pedica, Gajate, Bulotta, Gregorc and Cangi.)
- Published
- 2022
- Full Text
- View/download PDF
15. Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer.
- Author
-
Gregorc V, Mazzarella L, Lazzari C, Graziano P, Vigneri P, Genova C, Toschi L, Ciliberto G, Bonanno L, Delmonte A, Bucci G, Rossi A, Motta G, Coco S, Marinello A, Buglioni S, Cangi MG, Di Micco C, Bandiera A, Bonfiglio S, Pecciarini L, Guida A, Ceol A, Frige' G, De Maria R, and Pelicci PG
- Subjects
- Humans, Early Detection of Cancer, Genomics, Italy, Mass Screening methods, Precision Medicine methods, Prospective Studies, Sensitivity and Specificity, Validation Studies as Topic, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms diagnosis, Lung Neoplasms genetics
- Abstract
Background: The deeper knowledge of non-small-cell lung cancer (NSCLC) biology and the discovery of driver molecular alterations have opened the era of precision medicine in lung oncology, thus significantly revolutionizing the diagnostic and therapeutic approach to NSCLC. In Italy, however, molecular assessment remains heterogeneous across the country, and numbers of patients accessing personalized treatments remain relatively low. Nationwide programs have demonstrated that the creation of consortia represent a successful strategy to increase the number of patients with a molecular classification., Patients and Methods: The Alliance Against Cancer (ACC), a network of 25 Italian Research Institutes, has developed a targeted sequencing panel for the detection of genomic alterations in 182 genes in patients with a diagnosis of NSCLC (ACC lung panel). One thousand metastatic NSCLC patients will be enrolled onto a prospective trial designed to measure the sensitivity and specificity of the ACC lung panel as a tool for molecular screening compared to standard methods., Results and Conclusion: The ongoing trial is part of a nationwide strategy of ACC to develop infrastructures and improve competences to make the Italian research institutes independent for genomic profiling of cancer patients., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
16. Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor.
- Author
-
Schiavo Lena M, Cangi MG, Pecciarini L, Francaviglia I, Grassini G, Maire R, Partelli S, Falconi M, Perren A, and Doglioni C
- Subjects
- Adenocarcinoma, Mucinous diagnosis, Adenocarcinoma, Mucinous pathology, Biomarkers, Tumor genetics, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Papillary pathology, DNA Mutational Analysis, Humans, Male, Middle Aged, Neuroendocrine Tumors complications, Neuroendocrine Tumors diagnosis, Pancreatic Intraductal Neoplasms diagnosis, Pancreatic Intraductal Neoplasms genetics, Pancreatic Neoplasms complications, Carcinoma, Pancreatic Ductal pathology, Neuroendocrine Tumors pathology, Pancreatic Intraductal Neoplasms pathology, Pancreatic Neoplasms pathology
- Abstract
Recently, the term mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) has been proposed as an umbrella definition covering different possible combinations of mixed neuroendocrine-exocrine neoplasms. Among these, the adenoma plus neuroendocrine tumor (NET) combination is among the rarest and not formally recognized by the 2019 WHO Classification. In this setting, the debate between either collision tumors or true mixed neoplasms is still unsolved. In this report, a pancreatic intraductal papillary mucinous neoplasm (IPMN) plus a NET is described, and the molecular investigations showed the presence in both populations of the same KRAS, GNAS, and CDKN2A mutations and the amplification of the CCND1 gene. These data prove clonality and support a common origin of both components, therefore confirming the true mixed nature. For this reason, mixed neuroendocrine-exocrine neoplasms, in which the exocrine component is represented by a glandular precursor lesion (adenoma/IPMN) only, should be included into the MiNEN family.
- Published
- 2021
- Full Text
- View/download PDF
17. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.
- Author
-
Gregorc V, Lazzari C, Mandalá M, Ippati S, Bulotta A, Cangi MG, Khater A, Viganò MG, Mirabile A, Pecciarini L, Ogliari FR, Arrigoni G, Grassini G, Veronesi G, and Doglioni C
- Abstract
Tailored therapies based on the identification of molecular targets currently represent a well-established therapeutic scenario in the treatment of non-small cell lung cancer (NSCLC) patients. However, while aiming to improve patients' response to therapy, development of resistance is frequently observed in daily clinical practice. Intratumoral heterogeneity is a frequent event in NSCLC, responsible for several critical issues in patients' diagnosis and treatment. Advances in single-cell sequencing technologies have allowed in-depth profiling of tumors and attributed intratumoral heterogeneity to genetic, epigenetic, and protein modification driven diversities within cancer cell populations. This review highlights current research on the biological role of tumor heterogeneity and its impact on the development of acquired resistance in NSCLC patients.
- Published
- 2021
- Full Text
- View/download PDF
18. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
- Author
-
Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, Pecciarini L, Donadoni G, Fumagalli L, Sassone M, Calimeri T, Rossi G, Spina M, and Re A
- Subjects
- Adult, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Burkitt Lymphoma complications, Carmustine administration & dosage, Carmustine adverse effects, Carmustine therapeutic use, Cytarabine administration & dosage, Cytarabine adverse effects, Etoposide administration & dosage, Etoposide adverse effects, Etoposide therapeutic use, Female, HIV Infections complications, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Lymphoma, B-Cell complications, Male, Melphalan administration & dosage, Melphalan adverse effects, Melphalan therapeutic use, Middle Aged, Transplantation, Autologous adverse effects, Acquired Immunodeficiency Syndrome complications, Acquired Immunodeficiency Syndrome therapy, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Burkitt Lymphoma therapy, Cytarabine therapeutic use, Lymphoma, B-Cell therapy
- Abstract
A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with high rates of interruptions, severe mucositis, septic complications, and fungal infections. Here, we report the results of a multicentre phase II trial addressing a new dose-dense, short-term therapy aimed at maintaining efficacy and improving tolerability. The experimental programme included a 36-day polychemotherapy induction followed by high-dose cytarabine-based consolidation and response-tailored BEAM (carmustine, etoposide, cyatarabine, and melphalan)- conditioned autologous stem cell transplantation (ASCT). This therapy would be considered active if ≥11 complete remissions (CR) after induction (primary endpoint) were recorded among 20 assessable patients. HIV-positive adults (median age 42, range 26-58; 16 males) with untreated BL (n = 16), HGBL (n = 3) or double-hit lymphoma (n = 1) were enrolled. All patients had high-risk features, with meningeal and bone marrow infiltration in five and nine patients respectively. The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections). Response after induction (median duration: 47 days; interquartile range 41-54), was complete in 13 patients and partial in five [overall response rate = 90%; 95% confidence interval (CI) = 77-100]. All responders received consolidation, and five required autologous stem cell transplant. At a median follow-up of 55 (41-89) months, 14 patients are relapse-free and 15 are alive, with a five-year progression-free survival and an overall survival of 70% (95% CI = 60-80%) and 75% (95% CI = 66-84) respectively. No patient with cerebrospinal fluid (CSF)/meningeal lymphoma experienced central nervous system recurrence. With respect to previously reported regimens, this programme was delivered in a shorter period, and achieved the main goal of maintaining efficacy and improving tolerability., (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
19. Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities.
- Author
-
Lazzari C, Bulotta A, Cangi MG, Bucci G, Pecciarini L, Bonfiglio S, Lorusso V, Ippati S, Arrigoni G, Grassini G, Doglioni C, and Gregorc V
- Abstract
Lung cancer remains the first cause of cancer-related deaths worldwide. Thanks to the improvement in the knowledge of the biology of non-small cell lung cancer (NSCLC), patients' survival has significantly improved. A growing number of targetable molecular alterations have been identified. Next-generation sequencing (NGS) has become one of the methodologies entered in clinical practice and was recently recommended by the European society for medical oncology (ESMO) to perform a comprehensive molecular characterization in patients with cancer. The current review provides an overview of the clinical trials that have explored the impact of NGS in patients with cancer, its limits, and advantages.
- Published
- 2020
- Full Text
- View/download PDF
20. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.
- Author
-
Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, di Bergamo LT, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, and Bertoni F
- Subjects
- Humans, Lymphoma, B-Cell, Marginal Zone classification, Prognosis, Biomarkers, Tumor genetics, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, High-Throughput Nucleotide Sequencing methods, Lymphoma, B-Cell, Marginal Zone genetics, Lymphoma, B-Cell, Marginal Zone pathology
- Published
- 2019
- Full Text
- View/download PDF
21. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
- Author
-
Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart CE, Bulotta A, Gregorc V, Pecciarini L, Doglioni C, and Cangi MG
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Female, High-Throughput Nucleotide Sequencing, Humans, In Situ Hybridization, Fluorescence, Liquid Biopsy, Lung Neoplasms drug therapy, Male, Middle Aged, Molecular Targeted Therapy, Positron Emission Tomography Computed Tomography, Protein Kinase Inhibitors therapeutic use, Biomarkers, Tumor, Circulating Tumor DNA, DNA, Neoplasm, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Mutation
- Abstract
Objectives: Circulating cell-free tumor DNA (ctDNA) isolated from the peripheral blood of non-small-cell lung cancer (NSCLC) patients provides biomarkers for both therapeutic target selection, particularly when direct tumor biopsy is unfeasible, and also for drug resistance monitoring. This study evaluates the reliability and feasibility of ctDNA analysis in an in-house clinical molecular diagnostic workflow., Materials and Methods: Mutation profiling by both standard methods and Next-Generation sequencing (NGS) was carried out and compared on 2 independent lung cancer patient cohorts. Cohort 1 consisted of 50 EGFR-mutated NSCLC patients, established on tumour biopsy, for whom ctDNA was collected at disease progression after TKI-inhibitor treatment and could be used to monitor drug resistance. Cohort 2 consisted of 50 newly diagnosed lung cancer patients for whom tumour biopsy was not possible and only ctDNA was available, providing the possibility of biomarker identification., Results: ctDNA analysis of Cohort 1 verified the persistence of the tumour-detected EGFR activating mutation at disease progression by both standard and NGS methods, in 84% and 92% of the cases respectively. The T790M EGFR resistance mutation was identified in 71% of the ctDNA EGFR mutated samples providing vital information for their disease management. In newly diagnosed Cohort 2 patients, EGFR activating mutations were detected in 16% of the patients by both standard and NGS analysis of ctDNA in peripheral blood, providing indication to targeted-therapy otherwise unavailable for this group of patients., Conclusion: The presented study investigated lung cancer ctDNA analysis, comparing conventional methods versus NGS sequencing, and demonstrated the successful use of plasma ctDNA as a template for targeted NGS tumor gene panel in an in-house routine clinical practice. More importantly, these data underline the advantages of the clinical application of ctDNA NGS analysis for identification of therapeutic targets, real-time monitoring of therapy, and resistance mechanisms in lung cancer patients., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
22. MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
- Author
-
Miserocchi E, Ferreri AJM, Giuffrè C, Cangi MG, Francaviglia I, Calimeri T, Ponzoni M, Pecciarini L, Bandello FM, and Modorati GM
- Subjects
- Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Humans, Intraocular Lymphoma diagnosis, Intraocular Lymphoma surgery, Male, Middle Aged, Polymerase Chain Reaction, Prospective Studies, Slit Lamp Microscopy, Vitrectomy, Vitreous Body metabolism, Vitreous Body pathology, Waldenstrom Macroglobulinemia diagnosis, Waldenstrom Macroglobulinemia surgery, Aqueous Humor metabolism, Biomarkers, Tumor genetics, DNA, Neoplasm genetics, Intraocular Lymphoma genetics, Mutation, Myeloid Differentiation Factor 88 genetics, Waldenstrom Macroglobulinemia genetics
- Abstract
Purpose: To detect the presence of MYD88 L265P mutation in the aqueous humor of patients with cytologically proven vitreoretinal lymphoma., Methods: Eight consecutive patients with bilateral vitreoretinal lymphoma (16 eyes) were prospectively evaluated. Genomic DNA was extracted from aqueous samples after paracentesis and vitreous humor samples after diagnostic vitrectomy. MYD88 codon 265 mutation was investigated by both amplification-refractory mutation system polymerase chain reaction approach and pyrosequencing assay in the aqueous humor of all patients and in the vitreous of 6 patients. A control group of 8 age-matched patients with established diagnosis of noninfectious uveitis was also tested for the presence of MYD88 L265P mutation in the aqueous humor., Results: Eight patients (three men, five women) with mean age of 69.5 years (range 50-85 years) were considered. All the patients tested for MYD88 L265P in the vitreous (six) were positive, and this result was consistent with cytological examination in all samples but one. The MYD88 L265P mutation was found in the aqueous of 6 patients (75%), and in 3 of them, the mutation was present in both eyes. Results of MYD88 L265P mutation in aqueous and vitreous sample were consistent in 7 of the 8 eyes with available samples. The aqueous humor of the noninfectious uveitis control group was negative for the detection of MYD88 L265P mutation., Conclusion: MYD88 mutation was detected in the aqueous humor of 75% of patients with cytologically proven vitreoretinal lymphoma. This technique may be considered as an additional diagnostic tool in the detection of the disease.
- Published
- 2019
- Full Text
- View/download PDF
23. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
- Author
-
Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, Marcatti M, Girlanda S, Tonon G, Ciceri F, Caligaris-Cappio F, Ferrarini M, and Ferrero E
- Subjects
- Bioreactors, Bortezomib pharmacology, Cell Adhesion, Cell Survival, Coculture Techniques, Drug Resistance, Endothelial Cells, Gelatin, Humans, Multiple Myeloma drug therapy, Stromal Cells, Tumor Microenvironment, Bone Marrow pathology, Cell Communication, Cell Culture Techniques, Models, Biological, Multiple Myeloma pathology
- Abstract
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone marrow interactions are needed to fully investigate multiple myeloma pathogenesis and response to drugs. To this purpose, we exploited the 3D Rotary Cell Culture System bioreactor technology for myeloma-bone marrow co-cultures in gelatin scaffolds. The model was validated with myeloma cell lines that, as assessed by histochemical and electron-microscopic analyses, engaged contacts with stromal cells and endothelial cells. Consistently, pro-survival signaling and also cell adhesion-mediated drug resistance were significantly higher in 3D than in 2D parallel co-cultures. The contribution of the VLA-4/VCAM1 pathway to resistance to bortezomib was modeled by the use of VCAM1 transfectants. Soluble factor-mediated drug resistance could be also demonstrated in both 2D and 3D co-cultures. The system was then successfully applied to co-cultures of primary myeloma cells-primary myeloma bone marrow stromal cells from patients and endothelial cells, allowing the development of functional myeloma-stroma interactions and MM cell long-term survival. Significantly, genomic analysis performed in a high-risk myeloma patient demonstrated that culture in bioreactor paralleled the expansion of the clone that ultimately dominated in vivo Finally, the impact of bortezomib on myeloma cells and on specialized functions of the microenvironment could be evaluated. Our findings indicate that 3D dynamic culture of reconstructed human multiple myeloma microenvironments in bioreactor may represent a useful platform for drug testing and for studying tumor-stroma molecular interactions., (Copyright© 2018 Ferrata Storti Foundation.)
- Published
- 2018
- Full Text
- View/download PDF
24. Establishment, characterization and long-term culture of human endocrine pancreas-derived microvascular endothelial cells.
- Author
-
Sordi V, Ferri A, Ceserani V, Ciusani E, Dugnani E, Pellegrini S, Nano R, Pecciarini L, Pessina A, Pascucci L, Piemonti L, and Alessandri G
- Subjects
- Antigens, CD metabolism, Cadherins metabolism, Cells, Cultured, Endothelial Cells cytology, Humans, Interleukin-8 metabolism, Microvessels cytology, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor Receptor-1, von Willebrand Factor metabolism, Endothelial Cells metabolism, Endothelium, Vascular cytology, Islets of Langerhans cytology
- Abstract
Background: In vitro primary cultures of microvascular endothelial cells from endocrine pancreas are difficult to obtain, but can be a very helpful tool for studies of islet biology, transplantation and regenerative medicine., Methods: We applied a protocol recently described for the isolation and culture of brain microvascular endothelial cells (EC) on human pancreatic islets. EC obtained were characterized in terms of morphological (light and transmission electron microscopy), phenotypical (by immunofluorescence and flow cytometry) and functional (cord formation assay and protein secretion by multiplex bead-based assay) characteristics., Results: EC were obtained from 25% of islet preparations processed. Two primary endothelial cell lines showed high proliferative potential and were deeply characterized: they presented endothelial cell morphology and expressed CD31, CD49a, CD49e, CD34, von Willebrand Factor (vWF), Vascular Endothelial CAdherin (VE-CAD), Tyrosine Kinase with Ig and EGF Homology Domains-2 (TIE2), Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), Ulex lectin and the endothelium endocrine-specific marker nephrin. Besides, they were able to form cordons in vitro and secreted factors involved in the process of angiogenesis such as Vascular Endothelial Growth Factor (VEGF), Monocyte Chemotactic Protein 1 (MCP-1), interleukin (IL)-8 and Melanoma Growth Stimulatory Activity Alpha (GROα). These cell lines were termed Human Islet Microvascular Endothelial Cells (HIMEC)., Discussion: This study establishes a simple and effective strategy for isolation and long-term culture of EC derived from human pancreatic islet. HIMEC in culture preserve phenotype and functional properties and are, therefore, a useful tool for future experiments of in vitro pancreas modelling, co-transplantation with pancreatic islets, re-vascularization of scaffold or matrix for regenerative medicine purposes., (Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
25. Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.
- Author
-
Mezzapelle R, Rrapaj E, Gatti E, Ceriotti C, Marchis FD, Preti A, Spinelli AE, Perani L, Venturini M, Valtorta S, Moresco RM, Pecciarini L, Doglioni C, Frenquelli M, Crippa L, Recordati C, Scanziani E, de Vries H, Berns A, Frapolli R, Boldorini R, D'Incalci M, Bianchi ME, and Crippa MP
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Cisplatin therapeutic use, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Female, HMGB1 Protein metabolism, Humans, Immunocompetence, Mesothelioma, Malignant, Mice, Inbred BALB C, Neoplasm Transplantation, Pemetrexed therapeutic use, Survival Analysis, Gemcitabine, Lung Neoplasms blood supply, Lung Neoplasms drug therapy, Lung Neoplasms immunology, Lung Neoplasms pathology, Mesothelioma blood supply, Mesothelioma drug therapy, Mesothelioma immunology, Mesothelioma pathology
- Abstract
Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and respond to treatments used for MM patients. Our system largely recapitulates human mesothelioma, and we advocate its use for the study of MM development and treatment.
- Published
- 2016
- Full Text
- View/download PDF
26. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
- Author
-
Magliacane G, Grassini G, Bartocci P, Francaviglia I, Dal Cin E, Barbieri G, Arrigoni G, Pecciarini L, Doglioni C, and Cangi MG
- Subjects
- Base Sequence, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors genetics, GTP Phosphohydrolases genetics, Genotyping Techniques methods, High-Throughput Nucleotide Sequencing methods, Humans, Membrane Proteins genetics, Mutation genetics, Neoplasms diagnosis, Phosphatidylinositol 3-Kinases genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Reproducibility of Results, Retrospective Studies, DNA Mutational Analysis methods, Molecular Diagnostic Techniques methods, Neoplasms genetics, Polymorphism, Single Nucleotide genetics, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods
- Abstract
Tumor genotyping is an essential step in routine clinical practice and pathology laboratories face a major challenge in being able to provide rapid, sensitive and updated molecular tests. We developed a novel mass spectrometry multiplexed genotyping platform named PentaPanel to concurrently assess single nucleotide polymorphisms in 56 hotspots of the 5 most clinically relevant cancer genes, KRAS, NRAS, BRAF, EGFR and PIK3CA for a total of 221 detectable mutations. To both evaluate and validate the PentaPanel performance, we investigated 1025 tumor specimens of 6 different cancer types (carcinomas of colon, lung, breast, pancreas, and biliary tract, and melanomas), systematically addressing sensitivity, specificity, and reproducibility of our platform. Sanger sequencing was also performed for all the study samples. Our data showed that PentaPanel is a high throughput and robust tool, allowing genotyping for targeted therapy selection of 10 patients in the same run, with a practical turnaround time of 2 working days. Importantly, it was successfully used to interrogate different DNAs isolated from routinely processed specimens (formalin-fixed paraffin embedded, frozen, and cytological samples), covering all the requirements of clinical tests. In conclusion, the PentaPanel platform can provide an immediate, accurate and cost effective multiplex approach for clinically relevant gene mutation analysis in many solid tumors and its utility across many diseases can be particularly relevant in multiple clinical trials, including the new basket trial approach, aiming to identify appropriate targeted drug combination strategies.
- Published
- 2015
- Full Text
- View/download PDF
27. Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.
- Author
-
Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, and Scielzo C
- Published
- 2015
- Full Text
- View/download PDF
28. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.
- Author
-
Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, and Scielzo C
- Subjects
- Animals, Cell Line, Tumor, Gene Rearrangement, Humans, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Mice, Neoplasm Transplantation, Phenotype, ZAP-70 Protein-Tyrosine Kinase metabolism, CD5 Antigens metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology
- Abstract
Immortalized cell lines representative of chronic lymphocytic leukemia (CLL) can assist in understanding disease pathogenesis and testing new therapeutic agents. At present, very few representative cell lines are available. We here describe the characterization of a new cell line (PCL12) that grew spontaneously from the peripheral blood (PB) of a CLL patient with progressive disease and EBV infection. The CLL cell origin of PCL12 was confirmed after the alignment of its IGH sequence against the "original" clonotypic sequence. The IGH gene rearrangement was truly unmutated and no CLL-related cytogenetic or genetic lesions were detected. PCL12 cells express CD19, CD20, CD5, CD23, low levels of IgM and IgD and the poor-outcome-associated prognostic markers CD38, ZAP70 and TCL1. In accordance with its aggressive phenotype the cell line is inactive in terms of LYN and HS1 phosphorylation. BcR signalling pathway is constitutively active and anergic in terms of p-ERK and Calcium flux response to α-IgM stimulation. PCL12 cells strongly migrate in vitro in response to SDF-1 and form clusters. Finally, they grow rapidly and localize in all lymphoid organs when xenotrasplanted in Rag2-/-γc-/- mice. PCL12 represents a suitable preclinical model for testing pharmacological agents.
- Published
- 2015
- Full Text
- View/download PDF
29. Uterine inflammatory myofibroblastic tumor in a 10-year-old girl presenting as polypoid mass.
- Author
-
Fraggetta F, Doglioni C, Scollo P, Pecciarini L, Ippolito M, Amico P, Pelosi G, and Ponzoni M
- Subjects
- Biomarkers, Tumor analysis, Child, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Inflammation, Lymphatic Metastasis, Neoplasms, Muscle Tissue blood, Neoplasms, Muscle Tissue pathology, Polyps blood, Uterine Neoplasms blood, Uterine Neoplasms pathology, Watchful Waiting, Biomarkers, Tumor blood, Neoplasms, Muscle Tissue diagnosis, Polyps diagnosis, Uterine Neoplasms diagnosis
- Published
- 2015
- Full Text
- View/download PDF
30. CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
- Author
-
Brunetto E, Ferrara AM, Rampoldi F, Talarico A, Cin ED, Grassini G, Spagnuolo L, Sassi I, Ferro A, Cuorvo LV, Barbareschi M, Piccinin S, Maestro R, Pecciarini L, Doglioni C, and Cangi MG
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized therapeutic use, Breast Neoplasms mortality, Breast Neoplasms pathology, Cell Death drug effects, Cell Line, Tumor, Cohort Studies, Disease-Free Survival, Female, Humans, Middle Aged, Neoadjuvant Therapy, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Predictive Value of Tests, Protein Stability, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-2 antagonists & inhibitors, Signal Transduction, Trastuzumab, Antibodies, Monoclonal, Humanized pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Receptor, ErbB-2 metabolism, cdc25 Phosphatases metabolism
- Abstract
The CDC25A-CDK2 pathway has been proposed as critical for the oncogenic action of human epidermal growth factor receptor 2 (HER2) in mammary epithelial cells. In particular, transgenic expression of CDC25A cooperates with HER2 in promoting mammary tumors, whereas CDC25A hemizygous loss attenuates the HER2-induced tumorigenesis penetrance. On the basis of this evidence of a synergism between HER2 and the cell cycle regulator CDC25A in a mouse model of mammary tumorigenesis, we investigated the role of CDC25A in human HER2-positive breast cancer and its possible implications in therapeutic response. HER2 status and CDC25A expression were assessed in 313 breast cancer patients and we found statistically significant correlation between HER2 and CDC25A (P = .007). Moreover, an HER2-positive breast cancer subgroup with high levels of CDC25A and very aggressive phenotype was identified (P = .005). Importantly, our in vitro studies on breast cancer cell lines showed that the HER2 inhibitor efficacy on cell growth and viability relied also on CDC25A expression and that such inhibition induces CDC25A down-regulation through phosphatidylinositol 3-kinase/protein kinase B pathway and DNA damage response activation. In line with this observation, we found a statistical significant association between CDC25A overexpression and trastuzumab-combined therapy response rate in two different HER2-positive cohorts of trastuzumab-treated patients in either metastatic or neoadjuvant setting (P = .018 for the metastatic cohort and P = .021 for the neoadjuvant cohort). Our findings highlight a link between HER2 and CDC25A that positively modulates HER2-targeted therapy response, suggesting that, in HER2-positive breast cancer patients, CDC25A overexpression affects trastuzumab sensitivity.
- Published
- 2013
- Full Text
- View/download PDF
31. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation.
- Author
-
Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, Rosano C, Dei Tos AP, Doglioni C, and Maestro R
- Subjects
- Animals, Cell Transformation, Neoplastic, DNA Copy Number Variations, Epithelial-Mesenchymal Transition, Humans, Mice, Mice, Nude, Nuclear Proteins biosynthesis, Nuclear Proteins genetics, Phosphorylation, Proto-Oncogene Proteins c-mdm2 biosynthesis, RNA Interference, RNA, Small Interfering, Repressor Proteins metabolism, Twist-Related Protein 1 biosynthesis, Twist-Related Protein 1 genetics, Nuclear Proteins metabolism, Proto-Oncogene Proteins c-mdm2 metabolism, Sarcoma metabolism, Tumor Suppressor Protein p53 metabolism, Twist-Related Protein 1 metabolism
- Abstract
Twist proteins have been shown to contribute to cancer development and progression by impinging on different regulatory pathways, but their mechanism of action is poorly defined. By investigating the role of Twist in sarcomas, we found that Twist1 acts as a mechanism alternative to TP53 mutation and MDM2 overexpression to inactivate p53 in mesenchymal tumors. We provide evidence that Twist1 binds p53 C terminus through the Twist box. This interaction hinders key posttranslational modifications of p53 and facilitates its MDM2-mediated degradation. Our study suggests the existence of a Twist box code of p53 inactivation and provides the proof of principle that targeting the Twist box:p53 interaction might offer additional avenues for cancer treatment., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
32. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.
- Author
-
Fazi C, Scarfò L, Pecciarini L, Cottini F, Dagklis A, Janus A, Talarico A, Scielzo C, Sala C, Toniolo D, Caligaris-Cappio F, and Ghia P
- Subjects
- Adult, Aged, Aged, 80 and over, B-Lymphocytes pathology, Chromosomes, Human, Pair 12 genetics, Chromosomes, Human, Pair 13 genetics, Chromosomes, Human, Pair 17 genetics, Disease Progression, Female, Flow Cytometry, Follow-Up Studies, Humans, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Lymphocyte Count, Lymphocytosis diagnosis, Lymphocytosis metabolism, Male, Middle Aged, Receptors, Antigen, T-Cell, alpha-beta metabolism, T-Lymphocytes metabolism, T-Lymphocytes pathology, V(D)J Recombination genetics, B-Lymphocytes metabolism, Chromosome Aberrations, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Lymphocytosis genetics
- Abstract
Monoclonal B-cell lymphocytosis (MBL) is classified as chronic lymphocytic leukemia (CLL)-like, atypical CLL, and CD5(-) MBL. The number of B cells per microliter divides CLL-like MBL into MBL associated with lymphocytosis (usually detected in a clinical setting) and low-count MBL detected in the general population (usually identified during population screening). After a median follow-up of 34 months we reevaluated 76 low-count MBLs with 5-color flow cytometry: 90% of CLL-like MBL but only 44.4% atypical CLL and 66.7% CD5(-) MBL persisted over time. Population-screening CLL-like MBL had no relevant cell count change, and none developed an overt leukemia. In 50% of the cases FISH showed CLL-related chromosomal abnormalities, including monoallelic or biallelic 13q deletions (43.8%), trisomy 12 (1 case), and 17p deletions (2 cases). The analysis of the T-cell receptor β (TRBV) chains repertoire showed the presence of monoclonal T-cell clones, especially among CD4(high)CD8(low), CD8(high)CD4(low) T cells. TRBV2 and TRBV8 were the most frequently expressed genes. This study indicates that (1) the risk of progression into CLL for low-count population-screening CLL-like MBL is exceedingly rare and definitely lower than that of clinical MBL and (2) chromosomal abnormalities occur early in the natural history and are possibly associated with the appearance of the typical phenotype.
- Published
- 2011
- Full Text
- View/download PDF
33. HER2 testing in gastric cancer.
- Author
-
Albarello L, Pecciarini L, and Doglioni C
- Subjects
- Antibodies, Monoclonal, Humanized, Breast Neoplasms metabolism, Clinical Trials, Phase III as Topic, Esophagogastric Junction pathology, Gene Amplification, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Randomized Controlled Trials as Topic, Stomach Neoplasms genetics, Stomach Neoplasms metabolism, Stomach Neoplasms secondary, Trastuzumab, Antibodies, Monoclonal therapeutic use, Receptor, ErbB-2 genetics, Stomach Neoplasms drug therapy
- Abstract
Molecular therapies targeting HER2 are part of the established drug armamentarium in breast carcinoma. Now the ToGA trial, an international multicenter phase III clinical study, involving 24 countries globally, has shown that the anti-HER2 humanized monoclonal antibody Trastuzumab is effective in prolonging survival in HER2-positive carcinoma of the stomach and the gastroesophageal junction (GEJ). Similarly to breast carcinoma, >20% of gastric cancers show HER2 overexpression and/or amplification, and this percentage increases to 33% in GEJ tumors. Thus, as in breast carcinoma, pathologists are now asked to evaluate HER2 status in gastric carcinoma samples. As validated in the ToGA trial, the HER2 testing criteria that must be used in evaluating both gastric carcinoma biopsies and surgical specimens significantly differ from those routinely applied in breast carcinoma. The main variations with regard to the pattern of reactivity in HER2-expressing cells are as follows: the completeness of membrane staining is not a "conditio sine qua non" and the number of stained cells necessary to consider a case as positive is different. We must also take note of the much more frequent heterogeneity of HER2 positivity in gastric cancer compared with breast carcinoma and the less stringent correlation between HER2 amplification and protein overexpression that is observed in gastric carcinoma, where more than 20% of cases may carry HER2 amplification, although of low level, without HER2 expression. In these patients, in the ToGA trial, there was no apparent benefit from adding Trastuzumab to chemotherapy: for this reason the European Medicines Agency, while approving usage of Trastuzumab for metastatic adenocarcinoma treatment, indicated HER2 testing by immunohistochemistry as first evaluation assay, followed by fluorescence in situ hybridization in 2+ equivocal cases. HER2 testing in gastric carcinoma is a new field, opening several opportunities: for patients with gastric cancer, this is a new promising therapeutic option; for pathologists, strengthening our role in therapy selection and emphasizing our duty of providing accurate and reproducible HER2 testing results; for all interested in understanding the biology of gastric and GEJ cancer and in discovering new possible molecular therapy targets.
- Published
- 2011
- Full Text
- View/download PDF
34. Urocortin in amniotic fluid and Down syndrome.
- Author
-
Torricelli M, Voltolini C, Biliotti G, Giorlandino C, De Pascalis F, De Bonis M, Mesuraca A, Giovannelli A, Pecciarini L, and Petraglia F
- Subjects
- Adult, Amniocentesis, Case-Control Studies, Down Syndrome pathology, Female, Gestational Age, Humans, Pregnancy, Pregnancy Trimester, Second, Retrospective Studies, Amniotic Fluid metabolism, Down Syndrome metabolism, Urocortins metabolism
- Published
- 2009
- Full Text
- View/download PDF
35. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
- Author
-
Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, and Bertoni F
- Subjects
- B-Cell CLL-Lymphoma 10 Protein, Biomarkers, Tumor genetics, DNA-Binding Proteins genetics, Female, Gene Rearrangement, Humans, Immunohistochemistry, Immunophenotyping, Kaplan-Meier Estimate, Lymph Nodes pathology, Lymphoma, Large B-Cell, Diffuse mortality, Male, Middle Aged, Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein, Prognosis, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-myc genetics, Adaptor Proteins, Signal Transducing genetics, Caspases genetics, In Situ Hybridization, Fluorescence methods, Lymphoma, Large B-Cell, Diffuse genetics, Neoplasm Proteins genetics, Proto-Oncogene Proteins genetics
- Abstract
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Although it is a curable disease, fewer than half of patients are cured with conventional chemotherapy. The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and responses to therapy. We analyzed 74 cases of diffuse large B-cell lymphoma using interphase fluorescent in situ hybridization with commercially available probes for split-signal targeting BCL-2, BCL-6, MYC, BCL-10, and MALT-1. Gene rearrangements were identified in 48 (65%) of 74 cases. BCL-6 was the most rearranged gene (45%), followed by BCL-2 (21%), BCL-10 (18%), and MYC (16%). No MALT-1 rearrangements were found. When diffuse large B-cell lymphoma cases were subdivided into germinal-center B-cell-like and activated B-cell-like groups, an inverse pattern of BCL-2 and BCL-6 rearrangements was observed. Of interest, the presence of chromosome rearrangements was associated with a worse prognosis. The pattern of cytogenetic abnormalities highlighted the fact not only that diffuse large B-cell lymphoma is a heterogeneous entity but also that even individual cases may contain subclones bearing different chromosomal rearrangements. The relevance and the clinical implication of minor clones showing gene rearrangements are poorly understood; however, this first observation suggests that different rearrangements may be involved in the progression of the disease. The fluorescent in situ hybridization analysis with the panel used in this study is useful to detect the heterogeneity of diffuse large B-cell lymphomas and identify alterations with prognostic implications.
- Published
- 2009
- Full Text
- View/download PDF
36. Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods.
- Author
-
Ponzoni M, Ferreri AJ, Guidoboni M, Lettini AA, Cangi MG, Pasini E, Sacchi L, Pecciarini L, Grassi S, Dal Cin E, Stefano R, Magnino S, Dolcetti R, and Doglioni C
- Subjects
- Chlamydophila psittaci genetics, Chlamydophila psittaci isolation & purification, DNA, Bacterial analysis, Eye Neoplasms microbiology, Humans, Lymphoma microbiology, Macrophages microbiology, Monocytes microbiology, Polymerase Chain Reaction, Psittacosis epidemiology, Chlamydia Infections epidemiology, Eye Neoplasms epidemiology, Lymphoma epidemiology
- Abstract
Purpose: Chlamydia psittaci (Cp) has been associated to ocular adnexal lymphomas (OAL) with variable geographic distribution. Herein, we used multiple Chlamydia detection tools to identify Cp elementary bodies-containing cell and to assess Cp prevalence in both nodal and extranodal lymphomas., Experimental Design: TETR-PCR, immunohistochemistry, immunofluorescence, electron microscopy, and laser-capture microdissection were done in 35 OALs to define their effect in Chlamydia detection and, moreover, to identify the Cp cellular carrier. Cp prevalence was screened by TETR-PCR in 205 extraorbital lymphomas and 135 nonneoplastic controls., Results: Twenty-six (74%) OALs were associated with Cp infection: immunohistochemistry, immunofluorescence, and laser-capture microdissection-assisted PCR showed that monocytes/macrophages were the Cp carriers; electron microscopy showed the presence of intact Cp elementary bodies into these cells. Immunohistochemistry and TETR-PCR showed a 70% concordance rate (P = 0.001). Cp DNA was equally prevalent in non-OAL, nodal, and extranodal lymphomas: among the latter, it was more common in diffuse large B-cell lymphomas of the skin (P = 0.03) and Waldeyer's ring., Conclusions: This multiparametric approach shows, for the first time, that monocytes/macrophages are the carriers of Cp, Cp seems preferentially associated with lymphomas arising in organs primarily exposed to antigens. The clinical implications of these findings deserve to be prospectively investigated.
- Published
- 2008
- Full Text
- View/download PDF
37. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
- Author
-
Cangi MG, Piccinin S, Pecciarini L, Talarico A, Dal Cin E, Grassi S, Grizzo A, Maestro R, and Doglioni C
- Subjects
- Blotting, Western, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Cycle physiology, Cell Transformation, Neoplastic metabolism, Cells, Cultured, DNA Damage, Epithelial Cells pathology, Female, Fluorescent Antibody Technique, Humans, In Situ Hybridization, Fluorescence, Mammary Glands, Human pathology, Up-Regulation, Breast Neoplasms genetics, Cell Transformation, Neoplastic genetics, DNA Repair, Epithelial Cells metabolism, Mammary Glands, Human metabolism, cdc25 Phosphatases biosynthesis
- Abstract
CDC25A phosphatase, an essential component of the cell cycle machinery, is also a key player in integrating the specific signals of checkpoint control in response to DNA damage. There are several lines of evidence that indicate a role for CDC25A in cancer development, consistent with the fact that its overexpression is detected in human cancers. In particular we previously reported that CDC25A is overexpressed also in early breast carcinoma. Recent data suggest that oncogene activation during early stages of tumor development causes DNA replication stress resulting in the induction of DNA damage response (DDR) and that the selection of cells defecting in their DDR could lead to malignant progression. To address how CDC25A overexpression contributes to breast cancer development we established a cell model in which CDC25A was constitutively overexpressed in hTERT-immortalized primary human mammary epithelial cells. At the earliest passages following CDC25A transduction we observed DDR signs associated with unscheduled DNA replication origins. In the latest passages DDR was significantly impaired and, even after ionizing radiation exposition, cells failed to induce G1 and G2 checkpoints; moreover DNA replication stress conditions, such as aphidicolin treatment, highlighted increased fragile site breakages and destabilized chromosomes just in these latest passages cells. Our data suggest that CDC25A overexpression, pushing the cell through the cell cycle transitions, induces DDR alterations that might enhance genomic instability., (Copyright 2008 Wiley-Liss, Inc.)
- Published
- 2008
- Full Text
- View/download PDF
38. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study.
- Author
-
Ferreri AJ, Dolcetti R, Dognini GP, Malabarba L, Vicari N, Pasini E, Ponzoni M, Cangi MG, Pecciarini L, Resti AG, Doglioni C, Rossini S, and Magnino S
- Subjects
- Adult, Aged, Aged, 80 and over, Animal Husbandry, Case-Control Studies, Chlamydia Infections microbiology, Chlamydophila psittaci genetics, Chronic Disease, Conjunctivitis microbiology, DNA, Bacterial isolation & purification, Environmental Exposure adverse effects, Female, Humans, Leukocytes, Mononuclear microbiology, Male, Middle Aged, Occupational Exposure adverse effects, Polymerase Chain Reaction, Prospective Studies, Risk Factors, Chlamydia Infections complications, Chlamydophila psittaci isolation & purification, Chlamydophila psittaci pathogenicity, Conjunctival Neoplasms microbiology, Conjunctivitis complications, Lymphoma, B-Cell, Marginal Zone microbiology, Orbital Neoplasms microbiology
- Abstract
Ocular adnexal MALT lymphoma (OAML) is linked to Chlamydophila psittaci (Cp) infection. Viability and infectivity of Cp, demonstrated by growth in culture, has not been yet investigated in these patients. We conducted a single-center prospective case-control study to assess the prevalence, viability and infectivity of Cp in 20 OAML patients and 42 blood donors registered in a 6-month period. The presence of Cp in conjunctival swabs and peripheral blood mononuclear cells (PBMC) of patients and donors was assessed by TETR-PCR and in vitro cultures. From an epidemiological point of view, OAML patients often resided in rural areas, and reported a history of chronic conjunctivitis and prolonged contact with household animals (85% vs. 38% of donors; p = 0.00001). Cp was detected in lymphoma tissue in 15 (75%) patients. Cp DNA was detected in conjunctival swabs and/or PBMC from 10 (50%) patients and in PBMC from 1 (2%) donor (p = 0.01). Viability and infectivity of Cp, demonstrated by growth in culture, were confirmed in conjunctival swabs and/or PBMC from 5 (25%) patients, but not in donors (p = 0.002). This prospective study demonstrates, for the first time, that Cp present in the conjunctiva and PBMC of OAML patients is capable to grow and be isolated in cell cultures. Cp infection is common in OAML patients and exceptional in blood donors. Epidemiological data of OAML patients (prolonged contact with household animals and chronic conjunctivitis) are consistent with Cp exposure risk.
- Published
- 2008
- Full Text
- View/download PDF
39. A woman and her canary: a tale of chlamydiae and lymphomas.
- Author
-
Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, and Ponzoni M
- Subjects
- Animals, Anti-Bacterial Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bronchial Neoplasms diagnosis, Chlamydophila Infections drug therapy, Chlamydophila Infections microbiology, Chlamydophila Infections veterinary, Doxycycline therapeutic use, Eye Neoplasms drug therapy, Female, Humans, Immunohistochemistry, Liver microbiology, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell, Marginal Zone drug therapy, Middle Aged, Neoplasms, Second Primary diagnosis, Bird Diseases microbiology, Bronchial Neoplasms microbiology, Canaries microbiology, Chlamydophila Infections transmission, Chlamydophila psittaci isolation & purification, Eye Neoplasms microbiology, Lacrimal Apparatus microbiology, Lymphoma, B-Cell microbiology, Lymphoma, B-Cell, Marginal Zone microbiology, Neoplasms, Second Primary microbiology
- Published
- 2007
- Full Text
- View/download PDF
40. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient.
- Author
-
Pecciarini L, Cangi MG, Lo Cunsolo C, Macri' E, Dal Cin E, Martignoni G, and Doglioni C
- Subjects
- Amino Acid Sequence, Base Sequence, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors chemistry, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors genetics, Carcinoma, Renal Cell pathology, Chromosome Mapping, DNA Primers, Female, Gene Expression Regulation, Neoplastic, Gene Fusion, Helix-Loop-Helix Motifs, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Kidney Neoplasms pathology, Middle Aged, Molecular Sequence Data, Neoplasm Proteins chemistry, Neoplasm Proteins genetics, Polymerase Chain Reaction, Carcinoma, Renal Cell genetics, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 6, Kidney Neoplasms genetics, Translocation, Genetic
- Abstract
Renal-cell carcinoma (RCC) constitutes a heterogeneous group of tumors with specific chromosome aberrations. Recently, a new small group of RCC, occurring in children and young adults, has been described as characterized by t(6;11)(p21;q12). It has been shown that this translocation results in the fusion of the 5' portion of the ALPHA gene (11q12) with the transcription factor gene TFEB (6p21). Herewith, we report the first complete cytogenetic and molecular characterization of a t(6;11)-positive RCC of an adult patient, a 54-year-old woman. The tumor was histologically defined as RCC with peculiar features and it was negative for epithelial markers and positive for melanocytic markers. Chromosome QFQ banding analysis of short-term cultured cells from the RCC showed t(6;11)(p21;q12) as the sole cytogenetic abnormality. The translocation was confirmed by FISH analysis. RT-PCR analysis, performed on total RNA isolated from both neoplastic and normal tissue samples, revealed an ALPHA-TFEB chimeric transcript in the tumor sample; sequencing of the RT-PCR product defined a novel TFEB gene breakpoint cluster region, broader than the one reported thus far. Western blot analysis showed a band at the expected size of wild-type TFEB in the neoplastic tissue compared to the normal sample, supporting that the fusion gene does not encode for a chimeric protein but it causes an upregulation of the wild-type TFEB. Our data contribute to define better this rare RCC type, which is typical not only of childhood but can also be found in adulthood., ((c) 2007 Wiley-Liss, Inc.)
- Published
- 2007
- Full Text
- View/download PDF
41. A transcription-dependent micrococcal nuclease-resistant fragment of the urokinase-type plasminogen activator promoter interacts with the enhancer.
- Author
-
Ferrai C, Munari D, Luraghi P, Pecciarini L, Cangi MG, Doglioni C, Blasi F, and Crippa MP
- Subjects
- Animals, Chromatin chemistry, Chromatin genetics, Chromatin metabolism, Chromatin Immunoprecipitation, Micrococcal Nuclease chemistry, Rats, Urokinase-Type Plasminogen Activator genetics, Enhancer Elements, Genetic, Models, Genetic, Promoter Regions, Genetic, Transcription, Genetic, Urokinase-Type Plasminogen Activator biosynthesis
- Abstract
We show the interaction between the enhancer and the minimal promoter of urokinase-type plasminogen activator gene during active transcription by coupling micrococcal nuclease digestion of cross-linked, sonicated chromatin, and chromatin immunoprecipitation. This approach allowed the precise identification of the interacting genomic fragments, one of which is resistant to micrococcal nuclease cleavage. The interacting fragments form a single transcriptional control unit, as indicated by their common protein content. Furthermore, we show that the enhancer-MP interaction persists during the early stages of transcription and is lost upon alpha-amanitin treatment, indicating the requirement for active transcription. Our results support a looping model of interaction between the enhancer and the MP of the urokinase-type plasminogen activator gene.
- Published
- 2007
- Full Text
- View/download PDF
42. Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation.
- Author
-
Doglioni C, Piccinin S, Demontis S, Cangi MG, Pecciarini L, Chiarelli C, Armellin M, Vukosavljevic T, Boiocchi M, and Maestro R
- Subjects
- Antibodies, Monoclonal, Axin Protein, Cytoskeletal Proteins immunology, DNA Mutational Analysis, Genes, APC, Humans, Immunohistochemistry, Skin metabolism, Trans-Activators immunology, beta Catenin, Cell Nucleus metabolism, Cytoskeletal Proteins genetics, Cytoskeletal Proteins metabolism, Mutation, Skin Neoplasms metabolism, Trans-Activators genetics, Trans-Activators metabolism
- Abstract
To determine the role of beta-catenin pathway in human skin carcinogenesis, 135 non-melanoma skin tumors were analyzed for beta-catenin expression and gene mutations. Intense nucleo-cytoplasmic immunoreactivity for C terminus beta-catenin antibodies was observed in all pilomatricomas and in single cases of trichoepithelioma and squamous cell carcinoma showing peculiar signs of matrical differentiation. Moderate increase of beta-catenin nuclear staining was detected in a significant proportion of basal cell carcinomas, Bowen disease, spiroadenomas, and occasionally also in squamous cell carcinomas, but in these neoplasms only a limited fraction of tumor cells accumulated beta-catenin. Molecular analysis revealed that beta-catenin gene mutations are a peculiar feature of skin tumors with matrical differentiation and correlate with a pattern of intense and diffuse beta-catenin nuclear expression. In contrast, adenomatous polyposis coli (APC) and AXIN2 mutations were not involved in skin tumorigenesis. Analysis of Wnt pathway revealed that TCF-1 and MITF-M were selectively induced in the tumor types harboring beta-catenin mutations, indicating that a Wnt/beta-catenin pathway involving TCF-1 and MITF-M is activated in these tumors. Interestingly, high expression levels of TCF-3 were found in basal cell carcinomas and spiroadenomas. TCF-3 is reported to act as a negative modulator of beta-catenin degradation pathway. Thus, the moderate increase of beta-catenin nuclear staining detected in these tumor types might, at least in part, be due to a TCF-3-dependent mechanism. Finally, we found that the presence of beta-catenin mutations significantly correlated with loss of nuclear immunoreactivity for an antibody raised against the N terminus of beta-catenin (alphaABC). Thus, a combined analysis with C terminus-beta-catenin antibodies and alphaABC Ab may represent a powerful investigative approach for the detection of beta-catenin structural alterations.
- Published
- 2003
- Full Text
- View/download PDF
43. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
- Author
-
Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, and Doglioni C
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma therapy, Antineoplastic Agents therapeutic use, Breast Neoplasms pathology, Breast Neoplasms therapy, Chemotherapy, Adjuvant, DNA Primers chemistry, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Lymphatic Metastasis, Membrane Glycoproteins genetics, Middle Aged, Prognosis, Proteoglycans genetics, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Neoplasm metabolism, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Receptors, Estrogen genetics, Receptors, Estrogen metabolism, Receptors, Progesterone genetics, Receptors, Progesterone metabolism, Reverse Transcriptase Polymerase Chain Reaction, Stromal Cells pathology, Survival Rate, Syndecan-1, Syndecans, Adenocarcinoma metabolism, Breast Neoplasms metabolism, Membrane Glycoproteins metabolism, Proteoglycans metabolism
- Abstract
Background: Syndecan-1 is a transmembrane heparan sulphate proteoglycan that is involved in cell-cell adhesion, organization of cell-matrix adhesion, and regulation of growth factor signaling., Methods: Specimens from 254 consecutive breast carcinoma (BC) cases (110 N0, 144 N1/2) with long-term follow-up (median, 95 months) were immunostained for syndecan-1, estrogen receptor (ER), progesterone receptor (PgR), and p53; in 154 cases, c-erbB-2 status was known. Syndecan-1 mRNA and protein expression also were evaluated in 20 breast tissue samples (10 normal and tumor pairs)., Results: Syndecan-1 was expressed at high levels in 106 (42%) BCs; syndecan-1 up-regulation was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) studies. High syndecan-1 expression was associated with high histologic grade, large tumor size, high mitotic count, c-erbB-2 overexpression, and ER and PgR negative status. At univariate survival analysis syndecan overexpression was related to poor prognosis (P < 0.01 for both overall survival (OS) and disease-free survival). Bivariate survival analysis showed an additive adverse effect for syndecan-1 and c-erbB-2 overexpression. At multivariate analysis, syndecan-1 overexpression was independently associated with poor OS (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.08-2.69). High syndecan-1 expression also was of independent prognostic value for OS in the group of 102 ER-negative patients (HR, 2.42; 95% CI, 1.21-4.82). Stratifying patients on the basis of the type of adjuvant therapy given, high syndecan-1 expression was associated with a higher risk of death only in patients treated with the cyclophosphamide-methotrexate-fluorouracil regimen (HR, 1.9; P = 0.09); at multivariate analysis for OS, this association proved to be of independent statistical significance (P = 0.03; HR, 2.15)., Conclusions: Syndecan-1 is expressed at high levels in a significant percentage of breast carcinomas and is related to an aggressive phenotype and poor clinical behavior., (Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11515)
- Published
- 2003
- Full Text
- View/download PDF
44. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.
- Author
-
Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, and Doglioni C
- Subjects
- Biomarkers, Tumor analysis, Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinoma metabolism, Carcinoma pathology, Cell Nucleus, DNA Primers chemistry, DNA-Binding Proteins, Epithelial Cells cytology, Epithelial Cells metabolism, Female, Genetic Markers, Humans, Immunohistochemistry, Phosphoproteins genetics, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors, Tumor Suppressor Proteins, Breast cytology, Breast metabolism, Genes, Tumor Suppressor, Genes, p53, Membrane Proteins, Phosphoproteins metabolism, Trans-Activators
- Abstract
Myoepithelial cells (MCs) constitute the basal cell layer of normal mammary epithelia, and their identification is of particular diagnostic value because they are retained in most benign lesions while being lost in malignancy. Several MC immunocytochemical markers are currently available for diagnostic purposes, with special reference to smooth muscle-related antigens. p63 is a member of the p53 gene family, and its germline mutations are associated with severe mammary developmental defects in both rodents and humans. Different p63 isoforms have been identified, some of which (DeltaNp63) are preferentially expressed in the epithelial basal cells of different organs and have been considered as possible markers of stem cells/reserve cells. We investigated immunohistochemically 384 samples of normal and diseased human breast, including 300 invasive carcinomas, using four antibodies recognizing all p63 isoforms, or the DeltaNp63 isoforms. Twenty cytologic specimens were also investigated. Furthermore, snap-frozen tissue samples from three fibroadenomas and 10 invasive ductal carcinomas with their paired non-neoplastic tissues and three corresponding lymph node metastases were evaluated for the expression of p63 mRNA by RT-PCR. In normal breast tissue p63 immunoreactivity was confined to the nuclei of MCs. In all benign lesions p63-immunoreactive cells formed a continuous basal rim along the epithelial structures. Stromal cells, and in particular myofibroblasts, were consistently unreactive. Adenomyoepitheliomas showed nuclear staining in most neoplastic cells. A peripheral rim of p63-immunoreactive cells was retained surrounding lobular and ductal carcinoma in situ, although it was discontinuous as opposed to the normal structures. Invasive breast carcinomas were consistently devoid of nuclear p63 staining, with the exception of the two adenoid-cystic carcinomas, of the two ductal carcinomas with squamous metaplasia, and of 11 (4.6%) ductal carcinomas not otherwise specified, showing p63 immunoreactivity in a minor fraction (5-15%) of the neoplastic cells. In comparison with other MC markers, p63 was the most specific, being restricted exclusively to MCs, whereas antibodies to smooth muscle actin and, to a lesser extent, calponin also decorated stromal myofibroblasts. In the cytologic preparations p63 immunoreactivity was a consistent feature of "naked nuclei" and of a subset of cells surrounding benign epithelial clusters. RT-PCR experiments with primers specific for different p63 isoforms documented that normal tissues and fibroadenomas preferentially expressed the DeltaNp63 isoforms. Our study demonstrates that in normal and pathologic breast tissues MCs consistently express the DeltaNp63 isoforms. We suggest p63 as a reliable, highly specific, and sensitive MC marker in both histologic and cytologic preparations. Furthermore, because p63 immunoreactivity in adult epithelia is normally restricted to progenitor cells, it can be speculated that it might be a clue for the identification of the still elusive breast progenitor cells.
- Published
- 2001
- Full Text
- View/download PDF
45. The role of immunohistochemistry in the differential diagnosis of serous effusions.
- Author
-
Cangi MG, Pecciarini L, and Doglioni C
- Subjects
- Biomarkers, Carcinoma metabolism, Carcinoma pathology, Diagnosis, Differential, Epithelium metabolism, Epithelium pathology, Exudates and Transudates cytology, Humans, Mesothelioma metabolism, Mesothelioma pathology, Exudates and Transudates metabolism, Immunohistochemistry, Serous Membrane metabolism
- Published
- 2000
46. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].
- Author
-
Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, and Fletcher JA
- Subjects
- Adenocarcinoma, Follicular metabolism, Adenoma genetics, Adenoma metabolism, Adult, Aged, Carcinoma, Papillary genetics, Carcinoma, Papillary metabolism, Cell Line, Cell Nucleus metabolism, Child, DNA-Binding Proteins chemistry, DNA-Binding Proteins genetics, DNA-Binding Proteins pharmacology, Humans, Middle Aged, Oncogene Proteins, Fusion chemistry, Oncogene Proteins, Fusion genetics, PAX8 Transcription Factor, Paired Box Transcription Factors, Receptors, Cytoplasmic and Nuclear chemistry, Receptors, Cytoplasmic and Nuclear genetics, Response Elements, Thiazoles pharmacology, Thyroid Neoplasms metabolism, Trans-Activators chemistry, Trans-Activators genetics, Trans-Activators pharmacology, Transcription Factors chemistry, Transcription Factors genetics, Transcription Factors pharmacology, Transcription, Genetic, Transcriptional Activation, Translocation, Genetic, Adenocarcinoma, Follicular genetics, DNA-Binding Proteins physiology, Nuclear Proteins, Oncogene Proteins, Fusion physiology, Receptors, Cytoplasmic and Nuclear physiology, Thiazolidinediones, Thyroid Neoplasms genetics, Trans-Activators physiology, Transcription Factors physiology
- Abstract
Chromosomal translocations that encode fusion oncoproteins have been observed consistently in leukemias/lymphomas and sarcomas but not in carcinomas, the most common human cancers. Here, we report that t(2;3)(q13;p25), a translocation identified in a subset of human thyroid follicular carcinomas, results in fusion of the DNA binding domains of the thyroid transcription factor PAX8 to domains A to F of the peroxisome proliferator-activated receptor (PPAR) gamma1. PAX8-PPARgamma1 mRNA and protein were detected in 5 of 8 thyroid follicular carcinomas but not in 20 follicular adenomas, 10 papillary carcinomas, or 10 multinodular hyperplasias. PAX8-PPARgamma1 inhibited thiazolidinedione-induced transactivation by PPARgamma1 in a dominant negative manner. The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma.
- Published
- 2000
- Full Text
- View/download PDF
47. Small thymus in very low birth weight infants born to mothers with subclinical chorioamnionitis.
- Author
-
De Felice C, Toti P, Santopietro R, Stumpo M, Pecciarini L, and Bagnoli F
- Subjects
- Atrophy, Case-Control Studies, Chorioamnionitis diagnosis, Chorioamnionitis immunology, Chorioamnionitis metabolism, Female, Humans, Infant, Newborn, Male, Pregnancy, Radiography, Thymus Gland diagnostic imaging, Chorioamnionitis complications, Infant, Very Low Birth Weight, Thymus Gland pathology
- Abstract
Chorioamnionitis, a major cause of preterm birth with significant neonatal morbidity and mortality, frequently occurs in mothers who are free of symptoms. A combined clinical, radiologic, and pathologic study of 129 very low birth weight infants indicated a significant association between a markedly decreased thymic size at birth and subclinical chorioamnionitis.
- Published
- 1999
- Full Text
- View/download PDF
48. Decreased parathyroid hormone serum levels in pregnant women with first-trimester vaginal bleeding.
- Author
-
Bagnoli F, De Felice C, Massafra C, Pecciarini L, Bencini S, and Gioia D
- Subjects
- Adult, Female, Humans, Pregnancy, Pregnancy Trimester, First, Uterine Contraction, Metrorrhagia etiology, Parathyroid Hormone blood, Pregnancy Complications, Hematologic blood
- Published
- 1997
- Full Text
- View/download PDF
49. High incidence of histologic chorioamnionitis in women with gestational vaginal bleeding.
- Author
-
De Felice C, Toti P, Picciolini E, Massafra C, Pecciarini L, Palmeri ML, and Bracci R
- Subjects
- Adult, Case-Control Studies, Diagnosis, Differential, Female, Humans, Incidence, Pregnancy, Uterine Hemorrhage pathology, Chorioamnionitis complications, Chorioamnionitis pathology, Uterine Hemorrhage etiology
- Published
- 1997
- Full Text
- View/download PDF
50. Teriparatide acetate (hsPTH 1-34): a candidate drug for the prevention of preterm labor?
- Author
-
Bagnoli F, Molina E, De Felice C, Castelli MC, Pecciarini L, and De Leo V
- Subjects
- Adult, Animals, Female, Humans, In Vitro Techniques, Myometrium drug effects, Pregnancy, Rats, Obstetric Labor, Premature prevention & control, Teriparatide therapeutic use
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.